CA125 is a glycoprotein most commonly measured as a tumour marker in patients with ovarian cancer.
Occasionally CA125 may be measured in combination with human epididymis protein 4 (HE4) to calculate the ROMA score which is used to assess the likelihood that an adnexal mass is malignant.
Cancer Antigen 125 (NEW)
If overnight - Frozen
CA125 lacks sensitivity and specificity for any cancer and therefore it should not be used for screening or diagnostic purposes. However, CA125 may be monitored in a patient with a known CA125-secreting tumour (usually ovarian cancer) to assess for both response to treatment and recurrence or progression of known disease.
In addition to ovarian cancer, other cancers which may secrete CA125 include endometrial,cervical, liver and breast cancer.
0 – 35 kIU/L
Paramagnetic particle, chemiluminescent immunoassay performed on Beckman Coulter DxI 800
$34.12 (Exclusive of GST)
"*" indicates required fields